Literature DB >> 17390163

Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival.

Alfredo Guglielmi1, Andrea Ruzzenente, Marco Sandri, Silvia Pachera, Corrado Pedrazzani, Sebastiano Tasselli, Calogero Iacono.   

Abstract

BACKGROUND: Radio frequency ablation (RFA) of hepatocellular carcinoma has proved to be useful in local control of tumor. A few data on survival after treatment are available in literature. The aim of the study was to evaluate factors related to survival and to identify different classes of risk after radio frequency ablation.
METHODS: Ninety-eight cirrhotic patients with 145 hepatocellular carcinomas were treated with radio frequency ablation from January 1998 to May 2004. In 55 patients, cirrhosis was in Child-Pugh class A, and in 43, in class B. Tumor was single in 60 and multiple in 38; mean tumor number was 1.5 (range 1-3). Tumor size ranged from 1.5 to 6.0 cm, mean 3.8 cm. Mean follow up period was 24.9 months. Radio frequency ablation was performed with expandable type needle with percutaneous approach under real-time ultrasound guidance. For statistical analysis, univariate and multivariate analysis were performed.
RESULTS: Complete ablation of the tumor was achieved in 85.5% of lesions. Survival, 1 and 3 years, was 76.7 and 36.6%, respectively. Univariate analysis showed that Cancer of the Liver Italian Program (CLIP) score, tumor growth pattern, alpha-fetoprotein level, and complete tumor necrosis, were factors significantly related to poor survival. Multivariate analysis identified that factors related to poor survival were alpha-fetoprotein level >100 ng/ml, Child-Pugh class B, and incomplete tumor necrosis with a hazard ratio of 4.0, 2.7, and 3.8, respectively. After complete ablation, median survival was 38 months in patients with Child-Pugh class A cirrhosis and alpha-fetoprotein level < or =100 ng/ml, 22 months for patient with Child-Pugh class B cirrhosis and alpha-fetoprotein < or =100 ng/ml, and 9 months for patient with Child-Pugh class A cirrhosis and alpha-fetoprotein >100 ng/ml (P < 0.01).
CONCLUSIONS: Complete necrosis and absence of residual tumor positively affect survival after RFA. In patients with Child-Pugh A cirrhosis and alpha-fetoprotein level < or =100 radio frequency, ablation have results, 55% after 3 years, that are comparable to those of surgical resection. Patients with Child-Pugh B cirrhosis and/or alpha-fetoprotein >100 ng/ml showed less satisfactory results, and in these patients, multimodality treatment or other treatments should be considered.

Entities:  

Mesh:

Year:  2007        PMID: 17390163     DOI: 10.1007/s11605-006-0082-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model.

Authors:  S May; D W Hosmer
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

3.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

4.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 6.  Hepatocellular carcinoma: current management and future trends.

Authors:  Brian I Carr
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

8.  Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Arrigo Battocchia; Angelo Tonon; Girolamo Fracastoro; Claudio Cordiano
Journal:  Hepatogastroenterology       Date:  2003 Mar-Apr

9.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

10.  Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.

Authors:  Marco Vivarelli; Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Cucchetti; Roberto Bellusci; Claudio Cordiano; Antonino Cavallari
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

View more
  9 in total

1.  Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Valdegamberi; Silvia Pachera; Tommaso Campagnaro; Mirko D'Onofrio; Enrico Martone; Paola Nicoli; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

2.  Ultrasonogram of hepatocellular carcinoma is associated with outcome after radiofrequency ablation.

Authors:  Kosaku Moribata; Hideyuki Tamai; Naoki Shingaki; Yoshiyuki Mori; Tatsuya Shiraki; Shotaro Enomoto; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Masao Ichinose
Journal:  World J Hepatol       Date:  2012-12-27

3.  Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma.

Authors:  A Gallotti; M D'Onofrio; A Ruzzenente; E Martone; R De Robertis; A Guglielmi; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2009-09-05       Impact factor: 3.469

Review 4.  Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors.

Authors:  Hyeon Yu; Charles T Burke
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

5.  Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Tadashi Inuzuka; Haruhiko Takeda; Jun Nakajima; Fumihiro Matsuda; Azusa Sakamoto; Shinichiro Henmi; Keiichi Hatamaru; Tetsuro Ishikawa; Sumio Saito; Akihiro Nasu; Ryuichi Kita; Toru Kimura; Akira Arimoto; Yukio Osaki
Journal:  BMC Gastroenterol       Date:  2011-12-28       Impact factor: 3.067

6.  Post-operative pericardial effusion following treatment of small hepatocellular carcinoma with radiofrequency ablation: A case report.

Authors:  Zhebo Zhang; Zhuonan Zhuang; Zhenjie Xu; Qiang Mei; Kuansheng Ma; Xiaowu Li; Ping Bie
Journal:  Oncol Lett       Date:  2013-12-06       Impact factor: 2.967

7.  Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave?

Authors:  Sergio Sartori; Francesca Di Vece; Francesca Ermili; Paola Tombesi
Journal:  World J Radiol       Date:  2017-03-28

8.  Pure laparoscopic liver resection versus percutaneous radiofrequency ablation for small hepatocellular carcinoma: a propensity score and multivariate analysis.

Authors:  Kai-Chi Cheng; Kit-Man Ho
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

9.  Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience.

Authors:  Naveen Kalra; Mandeep Kang; Anmol Bhatia; Ajay K Duseja; Radha K Dhiman; Virendra K Arya; Arvind Rajwanshi; Yogesh K Chawla; Niranjan Khandelwal
Journal:  Indian J Radiol Imaging       Date:  2013-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.